Literature DB >> 29866745

The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo.

Amy Wahba1, Barbara H Rath1, John W O'Neill1, Kevin Camphausen1, Philip J Tofilon2.   

Abstract

Analysis of the radiation-induced translatome of glioblastoma stem-like cells (GSC) identified an interacting network in which XPO1 serves as a major hub protein. To determine whether this nuclear export protein provides a target for radiosensitization, we defined the effects of clinically relevant XPO1 inhibitor selinexor on the radiosensitivity of glioblastoma cells. As determined by clonogenic survival analysis, selinexor enhanced the radiosensitivity of GSCs but not normal fibroblast cell lines. On the basis of γH2AX foci and neutral comet analyses, selinexor inhibited the repair of radiation-induced DNA double-strand breaks in GSCs, suggesting that the selinexor-induced radiosensitization is mediated by an inhibition of DNA repair. Consistent with a role for XPO1 in the nuclear to cytoplasm export of rRNA, selinexor reduced 5S and 18S rRNA nuclear export in GSCs, which was accompanied by a decrease in gene translation efficiency, as determined from polysome profiles, as well as in protein synthesis. In contrast, rRNA nuclear export and protein synthesis were not reduced in normal cells treated with selinexor. Orthotopic xenografts initiated from a GSC line were then used to define the in vivo response to selinexor and radiation. Treatment of mice bearing orthotopic xenografts with selinexor decreased tumor translational efficiency as determined from polysome profiles. Although selinexor treatment alone had no effect on the survival of mice with brain tumors, it significantly enhanced the radiation-induced prolongation of survival. These results indicate that selinexor enhances the radiosensitivity of glioblastoma cells and suggest that this effect involves the global inhibition of gene translation. Mol Cancer Ther; 17(8); 1717-26. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29866745      PMCID: PMC6072610          DOI: 10.1158/1535-7163.MCT-17-1303

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  41 in total

1.  Comparison of the abundance of 10 radiation-induced proteins with their differential gene expression in L929 cells.

Authors:  S Szkanderová; M Port; J Stulík; L Hernychová; I Kasalová; D Van Beuningen; M Abend
Journal:  Int J Radiat Biol       Date:  2003-08       Impact factor: 2.694

2.  First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

Authors:  Albiruni R Abdul Razak; Morten Mau-Soerensen; Nashat Y Gabrail; John F Gerecitano; Anthony F Shields; Thaddeus J Unger; Jean R Saint-Martin; Robert Carlson; Yosef Landesman; Dilara McCauley; Tami Rashal; Ulrik Lassen; Richard Kim; Lee-Anne Stayner; Mansoor R Mirza; Michael Kauffman; Sharon Shacham; Amit Mahipal
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

3.  Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.

Authors:  Jasper E Neggers; Thomas Vercruysse; Maarten Jacquemyn; Els Vanstreels; Erkan Baloglu; Sharon Shacham; Marsha Crochiere; Yosef Landesman; Dirk Daelemans
Journal:  Chem Biol       Date:  2015-01-08

4.  Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.

Authors:  Joel G Turner; Douglas C Marchion; Jana L Dawson; Michael F Emmons; Lori A Hazlehurst; Peter Washausen; Daniel M Sullivan
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

5.  Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.

Authors:  Aiguo Shen; Yuchan Wang; Yueming Zhao; Lin Zou; Linlin Sun; Chun Cheng
Journal:  Neurosurgery       Date:  2009-07       Impact factor: 4.654

Review 6.  GammaH2AX and cancer.

Authors:  William M Bonner; Christophe E Redon; Jennifer S Dickey; Asako J Nakamura; Olga A Sedelnikova; Stéphanie Solier; Yves Pommier
Journal:  Nat Rev Cancer       Date:  2008-11-13       Impact factor: 60.716

7.  Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization.

Authors:  Chibawanye I Ene; Lincoln Edwards; Gregory Riddick; Mehmet Baysan; Kevin Woolard; Svetlana Kotliarova; Chen Lai; Galina Belova; Maggie Cam; Jennifer Walling; Ming Zhou; Holly Stevenson; Hong Sug Kim; Keith Killian; Timothy Veenstra; Rolanda Bailey; Hua Song; Wei Zhang; Howard A Fine
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

8.  NESdb: a database of NES-containing CRM1 cargoes.

Authors:  Darui Xu; Nick V Grishin; Yuh Min Chook
Journal:  Mol Biol Cell       Date:  2012-07-25       Impact factor: 4.138

Review 9.  The comet assay for DNA damage and repair: principles, applications, and limitations.

Authors:  Andrew R Collins
Journal:  Mol Biotechnol       Date:  2004-03       Impact factor: 2.860

10.  Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.

Authors:  Yoko Tabe; Kensuke Kojima; Shinichi Yamamoto; Kazumasa Sekihara; Hiromichi Matsushita; Richard Eric Davis; Zhiqiang Wang; Wencai Ma; Jo Ishizawa; Saiko Kazuno; Michael Kauffman; Sharon Shacham; Tsutomu Fujimura; Takashi Ueno; Takashi Miida; Michael Andreeff
Journal:  PLoS One       Date:  2015-09-04       Impact factor: 3.240

View more
  14 in total

1.  Radiation Drives the Evolution of Orthotopic Xenografts Initiated from Glioblastoma Stem-like Cells.

Authors:  Joseph H McAbee; Barbara H Rath; Kristin Valdez; Dejauwne L Young; Xiaolin Wu; Uma T Shankavaram; Kevin Camphausen; Philip J Tofilon
Journal:  Cancer Res       Date:  2019-10-15       Impact factor: 12.701

Review 2.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039

3.  Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity.

Authors:  Stacey L Lehman; Theresa Wechsler; Kayla Schwartz; Lauren E Brown; John A Porco; William G Devine; Jerry Pelletier; Uma T Shankavaram; Kevin Camphausen; Philip J Tofilon
Journal:  Mol Cancer Ther       Date:  2022-09-06       Impact factor: 6.009

Review 4.  The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.

Authors:  Jennifer R Landes; Stephen A Moore; Brooke R Bartley; Hung Q Doan; Peter L Rady; Stephen K Tyring
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-08       Impact factor: 4.322

Review 5.  The nuclear export protein XPO1 - from biology to targeted therapy.

Authors:  Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal:  Nat Rev Clin Oncol       Date:  2020-11-10       Impact factor: 66.675

6.  A Radiosensitivity Gene Signature and XPO1 Predict Clinical Outcomes for Glioma Patients.

Authors:  Shan Wu; Qiao Qiao; Guang Li
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

7.  XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.

Authors:  Zhi-Chuan Zhu; Ji-Wei Liu; Can Yang; Miao Zhao; Zhi-Qi Xiong
Journal:  Cell Death Dis       Date:  2019-05-21       Impact factor: 8.469

8.  Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-κB signaling pathway.

Authors:  Xuejiao Liu; Yiming Tu; Yifeng Wang; Di Zhou; Yulong Chong; Lin Shi; Guanzheng Liu; Xu Zhang; Sijin Wu; Huan Li; Shangfeng Gao; Mingshan Niu; Rutong Yu
Journal:  Cancer Cell Int       Date:  2020-03-30       Impact factor: 5.722

9.  Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.

Authors:  Rachel Sexton; Zaid Mahdi; Rahman Chaudhury; Rafic Beydoun; Amro Aboukameel; Husain Y Khan; Erkan Baloglu; William Senapedis; Yosef Landesman; Anteneh Tesfaye; Steve Kim; Philip A Philip; Asfar S Azmi
Journal:  Int J Mol Sci       Date:  2019-09-28       Impact factor: 5.923

Review 10.  Location, location, location: subcellular protein partitioning in proteostasis and aging.

Authors:  Anita V Kumar; Louis R Lapierre
Journal:  Biophys Rev       Date:  2021-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.